Drugs / Esketamine
last change 3 days ago re-read 2 minutes ago

Esketamine

Other / unclassified

Developed for
major depressive disorder · depressive disorder · chronic pain syndrome · sleep disorder · delirium · postpartum depression · tinnitus · anxiety
+37 more · breast cancer · postherpetic neuralgia · cognitive disorder · autism spectrum disorder · bipolar depression · fibromyalgia · infectious disease with sepsis · mixed anxiety and depressive disorder · subacute delirium · bipolar disorder · cardiac arrest · chronic rhinosinusitis · circadian rhythm sleep disorder · cognitive impairment with or without cerebellar ataxia · endometriosis · heart valve disorder · herpes zoster · immunodeficiency disease · inflammatory disease · insomnia · interstitial cystitis · irritable bowel syndrome · lung disorder · obstructive sleep apnea syndrome · post-traumatic stress disorder · Rett syndrome · separation anxiety disorder · sleep-wake disorder · tooth hard tissue disease · trigeminal neuralgia · acquired aneurysmal subarachnoid hemorrhage · complex regional pain syndrome · intracerebral hemorrhage · intrahepatic cholestasis of pregnancy · phimosis · subjective cognitive decline · traumatic brain injury
Investigated by
Janssen Research & Development, LLC · Peking University First Hospital · Beijing Tiantan Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Auris Medical AG · Beijing Ditan Hospital
+161 more · Beijing Xiaotangshan Hospital · Chinese PLA General Hospital · Hengshui People's Hospital · The First Hospital of Fangshan District,Beijing · Anqing Municipal Hospital · Eye & ENT Hospital of Fudan University · Nanjing First Hospital, Nanjing Medical University · Nanjing Medical University · Peking University Shenzhen Hospital · The Second Affiliated Hospital of Chongqing Medical University · The Second Hospital of Anhui Medical University · Women's Hospital School Of Medicine Zhejiang University · Beijing Friendship Hospital · Celon Pharma SA · Fujian Provincial Hospital · Medical University of Vienna · National Center for Research and Development, Poland · Peking University International Hospital · Second Affiliated Hospital of Wenzhou Medical University · The First Affiliated Hospital with Nanjing Medical University · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Yale University · Yangzhou University · Beijing Obstetrics and Gynecology Hospital · Dr. Inge Winter · Fujian Medical University Union Hospital · Hunan Provincial Maternal and Child Health Care Hospital · Hvidovre University Hospital · Janssen-Cilag International NV · Ling Dong · Northern Jiangsu People's Hospital · Obstetrics & Gynecology Hospital of Fudan University · Peking University · Qianfoshan Hospital · RenJi Hospital · The First Affiliated Hospital of Air Force Medicial University · The First Affiliated Hospital of Xiamen University · The First Hospital of Jilin University · The Second Hospital of Nanjing Medical University · The Second People's Hospital of Huai'an · Tianjin Medical University General Hospital · University Hospital, Basel, Switzerland · University of Aarhus · University of Münster · University of Sao Paulo · Zhejiang Cancer Hospital · Zhejiang University · Zhongda Hospital · Zhuan Zhang · Zylorion Health · bo xu · Aarhus University Hospital · Academic Medical Center - University of Amsterdam · Aerospace Center Hospital · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Ailin Luo · Air Force Military Medical University, China · Ambulance Amsterdam · American Foundation for Suicide Prevention · Andalusian Public Foundation for Health Research in Seville · Anna Meuronen, MD · Anshi Wu · Beijing 302 Hospital · Beijing Chaoyang District Maternal and Child Health Care Hospital · Beijing Chaoyang District Third Hospital · Beijing Daxing District Xinkang Hospital · Beijing Haidian Maternal and Child Health Hospital · Beijing Hospital · Beijing Sanbo Brain Hospital · Capital Medical University · Central Denmark Region · Centre Hospitalier Universitaire de Charleroi · Centre Hospitalier Universitaire de Liege · Centre Hospitalier Universitaire de Nice · all 167 on the full record

Regulatory milestones approvals, filings & regulatory actions · 4 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (2) US (FDA) SPRAVATO 2020-07-31 – 2025-01-17 fda.gov
Approved EU (EMA) Spravato 2019-12-18 europa.eu
Approved US (FDA) SPRAVATO 2019-03-05 fda.gov

Trials 257 · started per year

today
US approved 2019
EU approved 2019
1
2
3
3
2
2
11
9
10
6
2
4
17
25
28
27
37
39
28
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 011 trials
Phase 0 NCT07247968 Nov 2025 → Nov 2026 expected depressive disorder Min Su Recruiting No outcome recorded
Phase 0 NCT06784388 Jan 2025 → Dec 2027 expected major depressive disorder Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 0 NCT06559280 Aug 2024 → Aug 2025 ectopic pregnancy Fujian Provincial Hospital Completed No outcome recorded
Phase 0 NCT06199700 Nov 2023 → Dec 2025 Rett syndrome Children's Hospital of Fudan University Completed No outcome recorded
Phase 0 NCT06073015 Oct 2023 → Dec 2024 mixed anxiety and depressive disorder Henan Provincial People's Hospital Unknown No outcome recorded
Phase 0 NCT05943028 Jul 2023 → Oct 2024 bo xu Unknown No outcome recorded
Phase 0 NCT05242692 Jun 2022 → Aug 2025 delirium Affiliated Cancer Hospital & Institute of Guangzhou Medical University Completed No outcome recorded
Phase 0 NCT06370130 May → Dec 2022 Aerospace Center Hospital Completed No outcome recorded
Phase 0 NCT04777110 Aug 2021 → Aug 2022 depressive disorder First Affiliated Hospital of Chongqing Medical University Unknown No outcome recorded
Phase 0 NCT04757675 Mar → Sep 2021 separation anxiety disorder Eye & ENT Hospital of Fudan University Completed No outcome recorded
Phase 129 trials
Phase 1 NCT07603596 May 2026 → Apr 2028 expected delirium, digestive system neoplasm Qianfoshan Hospital Not yet recruiting No outcome recorded
Phase 1 NCT05571176 Jan → Jun 2023 Elina Brinck Unknown No outcome recorded
Phase 1 NCT05268497 Sep 2022 → Jun 2023 depressive disorder Janssen Research & Development, LLC Withdrawn No outcome recorded
Phase 1 NCT05320120 Jun 2022 → Jun 2023 Rupert Lanzenberger Completed No outcome recorded
Phase 1 NCT04587778 Oct 2020 → Mar 2025 major depressive disorder Medical University of Vienna Unknown No outcome recorded
Phase 1 NCT04300621 Jun → Aug 2020 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT04282746 Feb → Aug 2020 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT03808259 Dec 2018 → Sep 2019 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT03407872 Dec 2017 → May 2018 Celon Pharma SA Completed No outcome recorded
Phase 1 NCT03298906 Sep → Nov 2017 Janssen Research & Development, LLC Completed No outcome recorded
Phase 1/25 trials
Phase 1/2 NCT07131033 Sep 2025 → Jun 2026 gallbladder disorder The Second People's Hospital of Huai'an Completed No outcome recorded
Phase 1/2 NCT07034950 Jun 2025 → Jun 2028 expected liver cancer The First Affiliated Hospital of Xiamen University Active not recruiting No outcome recorded
Phase 1/2 NCT07034963 Jun 2025 → Jun 2028 expected adhesions of uterus, uterine polyp The First Affiliated Hospital of Xiamen University Active not recruiting No outcome recorded
Phase 1/2 NCT06795659 Jun 2025 → Jan 2026 post-traumatic stress disorder The University of Texas Health Science Center at San Antonio Completed No outcome recorded
Phase 1/2 NCT06920576 Mar → Jul 2025 overdue chronic rhinosinusitis The Second People's Hospital of Huai'an Active not recruiting No outcome recorded
Phase 216 trials
Phase 2 NCT06744361 Dec 2024 → Sep 2027 expected cardiac arrest Christian Hassager Recruiting No outcome recorded
Phase 2 NCT05438758 Jan 2023 → Feb 2024 major depressive disorder Zylorion Health Withdrawn No outcome recorded
Phase 2 NCT07212946 Oct 2022 → Oct 2024 major depressive disorder University of Sao Paulo Completed No outcome recorded
Phase 2 NCT05323019 Oct 2022 → Feb 2023 major depressive disorder Zylorion Health Terminated No outcome recorded
Phase 2 NCT05092152 Oct 2021 → Oct 2023 acute respiratory failure Federal University of São Paulo Completed No outcome recorded
Phase 2 NCT04867343 Jun 2021 → Aug 2023 Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 2 NCT03965871 Mar 2019 → Jan 2021 bipolar depression Celon Pharma SA Completed No outcome recorded
Phase 2 NCT03965858 Feb 2019 → Mar 2020 major depressive disorder Celon Pharma SA Completed No outcome recorded
Phase 2 NCT03185819 Oct 2017 → Mar 2023 major depressive disorder Janssen Research & Development, LLC Completed No outcome recorded
Phase 2 NCT02918318 Dec 2016 → Aug 2019 major depressive disorder Janssen Pharmaceutical K.K. Completed No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT06117917 Nov 2023 → May 2024 chronic pain syndrome Beijing Tiantan Hospital Unknown No outcome recorded
Phase 2/3 NCT05160493 Dec 2021 → Dec 2023 chronic pain syndrome Beijing Tiantan Hospital Completed No outcome recorded
Phase 2/3 NCT05096468 Dec 2021 → Jun 2022 spinal cord neoplasm Beijing Tiantan Hospital Completed No outcome recorded
Phase 2/3 NCT04425473 Feb 2021 → Jun 2024 depressive disorder Beijing Tiantan Hospital Completed No outcome recorded
Phase 2/3 NCT01275547 Jan → Jun 2011 spinal stenosis University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 326 trials
Phase 3 NCT07227454 Jan 2026 → Apr 2031 expected major depressive disorder Janssen Research & Development, LLC Recruiting No outcome recorded
Phase 3 NCT07153406 Sep 2025 → Sep 2026 expected depressive disorder Andalusian Public Foundation for Health Research in Seville Not yet recruiting No outcome recorded
Phase 3 NCT05603104 Apr 2025 → Jun 2028 expected bipolar depression, major depressive disorder, schizophrenia Dr. Inge Winter Recruiting No outcome recorded
Phase 3 NCT06713616 Jan 2025 → Dec 2030 expected depressive disorder Yale University Recruiting No outcome recorded
Phase 3 NCT05973851 Aug 2024 → Jun 2028 expected major depressive disorder Dr. Inge Winter Recruiting No outcome recorded
Phase 3 NCT06161805 Mar 2024 → Jan 2026 overdue chronic pain syndrome, endometriosis Reinier de Graaf Groep Recruiting No outcome recorded
Phase 3 NCT06051227 Jan 2024 → Mar 2026 overdue Academic Medical Center - University of Amsterdam Recruiting No outcome recorded
Phase 3 NCT06092684 Sep 2023 → Mar 2024 Chengdu Brilliant Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 3 NCT04924257 Jul 2021 → Aug 2023 major depressive disorder Medical University Innsbruck Withdrawn No outcome recorded
Phase 3 NCT04476446 Sep 2020 → Jun 2023 depressive disorder Janssen-Cilag, S.A. Completed No outcome recorded
Phase 478 trials
Phase 4 NCT07377981 Aug 2026 → Jan 2029 expected The First Affiliated Hospital with Nanjing Medical University Not yet recruiting No outcome recorded
Phase 4 NCT07644663 Jun → Aug 2026 overdue Fudan University Not yet recruiting No outcome recorded
Phase 4 NCT07570160 Jun 2026 → Nov 2027 expected Nanjing Children's Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07120477 Jun 2026 → Dec 2028 expected University of Sao Paulo Recruiting No outcome recorded
Phase 4 NCT07610343 Jun 2026 → Nov 2027 expected cognitive impairment with or without cerebellar ataxia, sleep disorder Peking University First Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07576543 Jun 2026 → Jun 2030 expected cognitive disorder Peking University First Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07639099 Jun 2026 → Oct 2029 expected postpartum depression Peking University First Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07576517 Jun 2026 → Jun 2029 expected cognitive disorder Peking University First Hospital Not yet recruiting No outcome recorded
Phase 4 NCT07179913 May → Nov 2026 expected depressive disorder The First Hospital of Jilin University Active not recruiting No outcome recorded
Phase 4 NCT07479602 Apr 2026 → Feb 2027 expected Peking University First Hospital Recruiting No outcome recorded
Phase not applicable86 trials
NCT07702240 Jul 2026 → Mar 2028 expected biliary tract disorder Ren Da Not yet recruiting No outcome recorded
NCT07665099 Jul 2026 → Jan 2027 expected cognitive disorder Xijing Hospital Not yet recruiting No outcome recorded
NCT07699523 Jun 2026 → Jun 2027 expected electroencephalographic peculiarity: fronto-precentral beta wave groups China-Japan Friendship Hospital Not yet recruiting No outcome recorded
NCT07625826 Jun 2026 → May 2027 expected The Second Hospital of Anhui Medical University Not yet recruiting No outcome recorded
NCT07641673 Jun 2026 → May 2027 expected The Second Hospital of Anhui Medical University Not yet recruiting No outcome recorded
NCT07324057 Apr 2026 → Feb 2027 expected autism spectrum disorder Sun Fei Recruiting No outcome recorded
NCT07315074 Mar → Dec 2026 expected circadian rhythm sleep disorder Zhuan Zhang Not yet recruiting No outcome recorded
NCT07374458 Feb → Dec 2026 expected Nanjing First Hospital, Nanjing Medical University Not yet recruiting No outcome recorded
NCT07374211 Jan 2026 overdue anxiety, breast cancer, depressive disorder Chinese PLA General Hospital Not yet recruiting No outcome recorded
NCT07374198 Jan 2026 overdue anxiety, breast cancer, depressive disorder Chinese PLA General Hospital Not yet recruiting No outcome recorded
Phase not stated1 trial
NCT03829579 major depressive disorder Janssen Research & Development, LLC Approved for marketing No outcome recorded
Also used as a comparator or background therapy in 40 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT06726382 Comparator Dec 2024 → Apr 2025 Helsinki University Central Hospital Completed No outcome recorded
Phase 24 trials
Phase 2 NCT07317206 Comparator Dec 2025 → Jun 2026 overdue post-traumatic stress disorder University of Sao Paulo Recruiting No outcome recorded
Phase 2 NCT05635955 Background Aug → Sep 2022 Maternal and Child Health Hospital of Hubei Province Completed No outcome recorded
Phase 2 NCT04666623 Comparator Nov 2020 → Oct 2023 University Hospital, Basel, Switzerland Withdrawn No outcome recorded
Phase 2 NCT03231683 Comparator Mar 2014 → May 2016 KK Women's and Children's Hospital Completed No outcome recorded
Phase 31 trial
Phase 3 NCT05839366 Comparator May 2023 → Oct 2024 infectious disease with sepsis Nanfang Hospital, Southern Medical University Unknown No outcome recorded
Phase 48 trials
Phase 4 NCT06613243 Comparator Oct → Dec 2024 Peking University First Hospital Completed No outcome recorded
Phase 4 NCT06278779 Comparator Jun 2024 → Apr 2027 expected The George Institute Recruiting No outcome recorded
Phase 4 NCT05095857 Comparator Sep 2023 → Sep 2028 expected acquired aneurysmal subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury Rigshospitalet, Denmark Recruiting No outcome recorded
Phase 4 NCT05655754 Comparator Nov 2022 → Oct 2025 overdue depressive disorder Medical University of Vienna Recruiting No outcome recorded
Phase 4 NCT04303325 Comparator Oct 2021 → Oct 2024 overdue depressive disorder China Medical University, China Recruiting No outcome recorded
Phase not applicable26 trials
NCT07597486 Comparator May 2026 → Jun 2027 expected Tianjin Medical University General Hospital Not yet recruiting No outcome recorded
NCT07560722 Comparator May 2026 → May 2027 expected intrahepatic cholestasis of pregnancy Tianjin Medical University General Hospital Not yet recruiting No outcome recorded
NCT07584902 Comparator Apr → Oct 2026 expected hepatobiliary disorder Gang Chen Not yet recruiting No outcome recorded
NCT07317219 Comparator Dec 2025 → Jun 2026 overdue University of Sao Paulo Recruiting No outcome recorded
NCT07317232 Comparator Dec 2025 → Jun 2026 overdue University of Sao Paulo Recruiting No outcome recorded

Evidence & citations 20 cited values

Every value below carries the sentence it was read from. 306 sources stand behind the page.

FieldValueCited text
Known as Esketamine “Dexmedetomidine-esketamine combination (1 μg/mL dexmedetomidine and 0.5 mg/mL esketamine) will be administered after anesthesia induction, firstly as a loading dose at a rate...” NCT07576517
245

“BACKGROUND: The objective of this study was to evaluate the efficacy and safety of esketamine hydrochloride injection (HR020602) in combination with propofol for the induction...” PMID 41545823 Jan 2026

“The patients received a single intravenous infusion of esketamine (0.2 mg/kg), which was added to 50 ml of normal saline and administered via a micro-infusion pump over 40 minutes.” NCT06968624

Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.” NCT06389344

Esketamine and propofol will be prepared shortly before injection by the nurse anesthetist as follows: 4 ml esketamine 25mg/ml, 6ml NaCl (0,9%), 10ml propofol (10mg/ml).” NCT05655754

Esketamine combined with pregabalin on acute postoperative pain in patients undergoing resection of spinal neoplasms: study protocol for a randomized controlled trial.” PMID 36841794 Feb 2023

“1. experimental group The patients were given intravenous injection of 0.25 mg / kg esketamine, 1.5 mg / kg propofol and 1 mg / kg succinylcholine in turn.” NCT07247968

“anaesthesia will be induced with 1.5-2.5 mg/kg propofol, 0.3-0.5 mg/kg esketamine, and 0.6-1.0 mg/kg rocuronium” NCT07603596

“lidocaine (1mg/kg), esketamine (0.5mg/kg), propofol (1-2mg/kg) and rocuronium (0.6mg/kg) were infused slowly” NCT05577962

“The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.” NCT06607029

Esketamine intranasal spray at flexible doses (28, 56 and 84 mg) once or twice a week” NCT07153406

Esketamine is the S-enantiomer of ketamine and twice as potent as racemic ketamine.” NCT07576543

Esketamine was used for induction and maintenance of anesthesia” NCT06367218

“propofol 2mg kg-1, esketamine 0.5 mg kg-1, rocuronium” NCT06493396

“Drug: EsketamineNCT06822088

NCT02418585

NCT06778460

NCT07034963

NCT07639099

NCT02918318

NCT06284668

NCT02417064

NCT06294639

NCT07479602

NCT05950646

NCT02060929

NCT02846519

NCT03039192

NCT04476446

NCT07641673

NCT02857777

NCT07422519

NCT05951465

NCT06398834

NCT05268497

NCT04850937

NCT02674295

NCT04938713

NCT07625826

NCT06617039

NCT06468436

NCT06103760

NCT07597486

NCT06784388

NCT02611505

NCT07002723

NCT03097133

NCT00847418

NCT01780259

NCT01980303

NCT06355180

NCT07053345

NCT05321160

NCT07644663

NCT07002801

NCT06073015

NCT06399185

NCT02568176

NCT06431386

NCT07212946

NCT06199011

NCT07179913

NCT07665099

NCT05323019

NCT07523334

NCT07523321

NCT07227454

NCT01394757

NCT07230171

NCT06566469

NCT06914193

NCT06300944

NCT05229913

NCT06608030

NCT06566482

NCT02129088

NCT05839366

NCT02919579

NCT03434041

NCT05554627

NCT03829579

NCT06370130

NCT01640080

NCT07125573

NCT03298906

NCT06778811

NCT05132595

NCT05964985

NCT07308756

NCT04553536

NCT06613243

NCT06051227

NCT06713616

NCT05450432

NCT06303037

NCT07131033

NCT06859892

NCT04924257

NCT05602428

NCT06658132

NCT05416073

NCT05155969

NCT05826327

NCT07064408

NCT06531837

NCT07584902

NCT06087510

NCT06773143

NCT05973851

NCT06900205

NCT07367542

NCT06199700

NCT06467513

NCT03756961

NCT06305221

NCT05698394

NCT04587778

NCT03185819

NCT02606084

NCT03421275

NCT05809804

NCT02094378

NCT07324057

NCT07151716

NCT02737605

NCT02154334

NCT06795659

NCT05283408

NCT04829318

NCT06003218

NCT06817239

NCT06430645

NCT04548973

NCT06543563

NCT02497287

NCT05289440

NCT06574945

NCT05686863

NCT06744361

NCT07556172

NCT06789185

NCT06624878

NCT04847245

NCT02133001

NCT05960942

NCT06914180

NCT06914206

NCT05341375

NCT04777110

NCT02782104

NCT07699523

NCT05438758

NCT07145775

NCT05464979

NCT05670561

NCT06788444

NCT06310785

NCT07315074

NCT04860661

NCT04599855

NCT04425473

NCT07570160

NCT02422186

NCT06062550

NCT06473285

NCT04666623

NCT05925283

NCT06729892

NCT04664530

NCT06432322

NCT07702240

NCT04682782

NCT04338321

NCT02228239

NCT05180318

NCT05732064

NCT04303325

NCT05752409

NCT04843462

NCT06451627

NCT05466708

NCT03407872

NCT05320120

NCT07560722

NCT05718544

NCT03965871

NCT04691076

NCT02343289

NCT07377981

NCT07369102

NCT05811221

NCT02345148

NCT07610343

NCT06414941

NCT05635955

NCT06726382

NCT04843982

NCT03231683

NCT06278779

NCT05943028

NCT07063108

NCT05582135

NCT05603975

NCT05122338

NCT06890897

NCT05011214

NCT04698434

NCT05551910

NCT07528651

NCT07374458

NCT06958393

NCT07062601

NCT07374211

NCT07374198

NCT05715671

NCT05515822

NCT06920576

NCT06853431

NCT05458453

NCT05497492

NCT06559280

NCT02682225

NCT06976996

NCT05643066

NCT05092152

NCT03965858

NCT02493868

NCT04613869

NCT06530706

NCT07120477

NCT06108830

NCT03852160

NCT01998958

NCT06388824

NCT07525999

NCT07050212

NCT06853041

NCT07034950

NCT06896994

NCT05718024

NCT07317232

NCT04597320

NCT07317219

NCT06161805

NCT07317206

NCT05506787

Known as (R,S)-ketamine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02717052
Known as AM-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01803646
5

NCT01934010

NCT00860808

NCT02040207

NCT02040194

NCT01270282

Known as BT-KTM-I ClinicalTrials.gov intervention name — accepted as the source's own label NCT06092684
Known as ESK “After surgery, patient-controlled intravenous analgesia will be established with dexmedetomidine (DEX 1.5 ug/ml), esketamine (ESK 0.5 mg/ml), and sufentanil (1.25 ug/ml),...” NCT07523321
6

“To investigate the efficacy and safety of propofol combined with different doses of esketamine (ESK) for anesthesia during loop electrosurgical excision procedure (LEEP).” NCT06574945

“After surgery, patient-controlled intravenous analgesia will be established with dexmedetomidine (DEX 1.5 ug/ml), esketamine (ESK 0.5 mg/ml), and sufentanil (1.25 ug/ml)” NCT07525999

Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD” PMID 37558912 Aug 2023

esketamine nasal spray (ESK) plus newly initiated oral antidepressant (OAD)” PMID 38557430 Apr 2024

Esketamine (ESK) shows potential as a rapid-acting analgesic in FM patients” PMID 42170615 May 2026

Esketamine (ESK) nasal spray” PMID 37568081 Aug 2023

Known as Esketamin “Low dose ketamine 0.1 mg/kg Product: Esketamin "Orifarm" 5 mg/ml” NCT05422001
Known as esketamine hydrochloride “BACKGROUND: The objective of this study was to evaluate the efficacy and safety of esketamine hydrochloride injection (HR020602) in combination with propofol for the induction...” PMID 41545823 Jan 2026
9

“OBJECTIVE: To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD).” PMID 29282469 Feb 2018

“The new analgesic anesthetic esketamine hydrochloride was launched in China last year” NCT04613869

Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]” NCT05464979

“Drug: esketamine hydrochlorideNCT06744361

“Drug: Esketamine hydrochlorideNCT06199700

Esketamine hydrochlorideNCT02345148

Esketamine hydrochlorideNCT05973851

NCT05603104

NCT06579937

Known as Esketamine Kalceks 5 mg/ml “Study drug dose (Esketamine Kalceks 5 mg/ml, 28 mg) p.o. at 9.00 a.m. on the study day.” NCT06726382
Known as HR020602 “BACKGROUND: The objective of this study was to evaluate the efficacy and safety of esketamine hydrochloride injection (HR020602) in combination with propofol for the induction...” PMID 41545823 Jan 2026
Known as JNJ-54135419 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04282746
Known as ketamine “intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD)” NCT06795659
1

“Intranasal ketamine (Esketamine)” NCT05438758

Known as Ketanest “In this investigator-initiated randomised, double-blinded, crossover study, adult healthy volunteers will be randomised to receive, as 60-second iv bolus injections on two...” NCT01506921
Known as low dose ketamine Low dose ketamine 0.1 mg/kg Product: Esketamin "Orifarm" 5 mg/ml” NCT05422001
Known as right ketamine “Esketamine, also known as right ketamine, has pharmacological characteristics similar to racemic ketamine while enhancing analgesic and sedative effects, helping to reduce...” NCT06559280
Known as S(+)-ketamine “A pre-prepared 50 ml syringe is utilized, containing 400 mcg of dexmedetomidine (4 ml), 50 mg of S-ketamine (2 ml), 400 mg of 2% lidocaine (20 ml), and 0.9% NaCl to a total...” NCT07084753
42

“Ketamine and its enantiomer S-ketamine (esketamine) are promising candidates to produce a rapid-onset antidepressant effect in treatment-resistant depression.” PMID 29736744 May 2018

“Patients were randomly assigned to receive an intravenous infusion of S(+)-ketamine (0.3 mg/kg/h) or 0.9% sodium chloride solution.” PMID 41209744 Nov 2025

“the enantiomer S-ketamine (esketamine) showed similar antidepressant efficacy with better safety in recent studies.” NCT04425473

“Participants will receive (S)-ketamine administered sublingually through OTF 1.” NCT04300621

NCT05060068

NCT04436250

NCT05242081

NCT04745286

NCT04757675

NCT01022840

NCT05160493

NCT00115102

NCT04657107

NCT04791059

NCT05571176

NCT05242692

NCT06117917

NCT00534586

NCT05414006

NCT04399070

NCT04459377

NCT03808259

NCT00209872

NCT00209885

NCT02543385

NCT05016128

NCT01275547

NCT04964219

NCT02624401

NCT05289050

NCT05922605

NCT04643132

NCT02994173

NCT04414943

NCT05304559

NCT05095857

NCT05212571

NCT04873479

NCT01506921

NCT05299866

NCT02717052

NCT03927378

Known as Spravato “BACKGROUND: Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for...” PMID 34696742 Oct 2021
5

“Intranasal esketamine (Spravato®), administered under medical supervision in accordance with FDA guidelines for treatment-resistant depression.” NCT07369102

Spravato nasal spray is the only esketamine product on the market used for the treatment of depression” NCT06726382

“Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]” NCT05464979

Spravato® (Esketamine) will be given intranasally.” NCT06713616

“56mg esketamine (2x Spravato® 28 mg nasal spray)” NCT05320120

Known as Spravato (for depression), Ketanest (for anesthesia) Spravato (for depression), Ketanest (for anesthesia)NCT05554627
Action Inhibit “NMDA receptor antagonist AM-101” PMID 28608739 Jun 2017
Modality Other / unclassified “Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses.” NCT05155969
Route Intranasal “after nasal application” NCT00847418